Literature DB >> 2297691

Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement.

M J Rudling1, B Angelin, C O Peterson, V P Collins.   

Abstract

The receptor binding of low density lipoprotein (LDL) was determined in homogenates of surgically removed specimens from primary and metastatic intracranial tumors and in some cases also from surrounding brain. Seventy-one specimens from 63 patients were analyzed. In a subsample of 16 specimens from 13 patients, the activity of 3-hydroxy-3-methylglutaryl-CoA reductase was assayed in parallel. The LDL binding in the tumors varied over a wide range. A significantly higher LDL binding activity was found when all tumor samples were compared to brain (P less than 0.05). In the three patients where LDL receptor and 3-hydroxy-3-methylglutaryl-CoA reductase activities were assayed in both tumor tissue and surrounding brain, it was found that the receptor or the enzyme activity was increased in the tumors. It is suggested that certain intracranial tumors have an increased cholesterol requirement and that this may be fulfilled by an enhanced LDL receptor activity or an increased 3-hydroxy-3-methylglutaryl-CoA reductase activity. The data indicate that the LDL receptor activity may be regulated independently of the reductase in intracranial tumors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297691

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Serum cholesterol in cerebral malignancies.

Authors:  P Grieb; M S Ryba; J Jagielski; W Gackowski; P Paczkowski; S J Chrapusta
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

2.  In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells.

Authors:  T Kikuchi; Y Nagata; T Abe
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

Review 3.  Molecular pathways: sterols and receptor signaling in cancer.

Authors:  Linara Gabitova; Andrey Gorin; Igor Astsaturov
Journal:  Clin Cancer Res       Date:  2013-10-24       Impact factor: 12.531

4.  An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.

Authors:  Deliang Guo; Felicia Reinitz; Mary Youssef; Cynthia Hong; David Nathanson; David Akhavan; Daisuke Kuga; Ali Nael Amzajerdi; Horacio Soto; Shaojun Zhu; Ivan Babic; Kazuhiro Tanaka; Julie Dang; Akio Iwanami; Beatrice Gini; Jason Dejesus; Dominique D Lisiero; Tiffany T Huang; Robert M Prins; Patrick Y Wen; H Ian Robins; Michael D Prados; Lisa M Deangelis; Ingo K Mellinghoff; Minesh P Mehta; C David James; Arnab Chakravarti; Timothy F Cloughesy; Peter Tontonoz; Paul S Mischel
Journal:  Cancer Discov       Date:  2011-09-15       Impact factor: 39.397

Review 5.  Lipid metabolism emerges as a promising target for malignant glioma therapy.

Authors:  Deliang Guo; Erica Hlavin Bell; Arnab Chakravarti
Journal:  CNS Oncol       Date:  2013-05

Review 6.  Targeting SREBP-1-driven lipid metabolism to treat cancer.

Authors:  Deliang Guo; Erica Hlavin Bell; Paul Mischel; Arnab Chakravarti
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

7.  Enhancement of sterol synthesis by the monoterpene perillyl alcohol is unaffected by competitive 3-hydroxy-3-methylglutaryl-CoA reductase inhibition.

Authors:  S R Cerda; J Wilkinson; S K Branch; S A Broitman
Journal:  Lipids       Date:  1999-06       Impact factor: 1.880

8.  Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins.

Authors:  Jean-Pierre H Perchellet; Elisabeth M Perchellet; Kyle R Crow; Keith R Buszek; Neil Brown; Sampathkumar Ellappan; Ge Gao; Diheng Luo; Machiko Minatoya; Gerald H Lushington
Journal:  Int J Mol Med       Date:  2009-11       Impact factor: 4.101

Review 9.  Attacking the supply wagons to starve cancer cells to death.

Authors:  Elizabeth M Selwan; Brendan T Finicle; Seong M Kim; Aimee L Edinger
Journal:  FEBS Lett       Date:  2016-03-22       Impact factor: 4.124

Review 10.  Targeting cancer using cholesterol conjugates.

Authors:  Awwad A Radwan; Fares K Alanazi
Journal:  Saudi Pharm J       Date:  2013-01-31       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.